The mystery of evacetrapib - why are CETP inhibitors failing?

Cholesteryl ester transfer protein (CETP) plays a pivotal role in lipoprotein metabolism, primarily by virtue of its ability to facilitate transfer of esterified cholesterol from high-density lipop...

• Publication year

  2020

• Venue

  Expert Review of Cardiovascular Therapy

• Publication date

  2020-03-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/14779072.2020.1745633PMID 32200670
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib.

  2020cited by this paper
• A Novel Role for CETP as Immunological Gatekeeper: Raising HDL to Cure Sepsis?

  2020cited by this paper
• Impact of ADCY9 Genotype on Response to Anacetrapib

  2019cited by this paper
• ADCY9 Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease: A Nested Case-Control Study

  2018cited by this paper
• Effects of Anacetrapib in Patients With Atherosclerotic Vascular Disease

  2018cited by this paper
• Therapy with cholesteryl ester transfer protein (CETP) inhibitors and diabetes risk.

  2018cited by this paper
• CETP inhibition, statins and diabetes.

  2018cited by this paper
• Evacetrapib and Cardiovascular Outcomes in High‐Risk Vascular Disease

  2017cited by this paper
• Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial.

  2017cited by this paper
• Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk

  2017cited by this paper
• Pharmacogenomic Determinants of the Cardiovascular Effects of Dalcetrapib

  2015cited by this paper
• Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study.

  2015cited by this paper
• Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial.

  2015cited by this paper
• Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects.

  2015cited by this paper
• ACP Journal Club: adding niacin plus laropiprant to statins did not reduce vascular events and increased serious adverse events.

  2014cited by this paper
• Effects of extended-release niacin with laropiprant in high-risk patients.

  2014cited by this paper
• High-density lipoprotein, beta cells, and diabetes .

  2014cited by this paper
• Lipids, Safety Parameters, and Drug Concentrations After an Additional 2 Years of Treatment With Anacetrapib in the DEFINE Study

  2014cited by this paper
• Effects of dalcetrapib in patients with a recent acute coronary syndrome.

  2012cited by this paper
• Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial.

  2012cited by this paper
• Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects.

  2012cited by this paper
• Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.

  2011cited by this paper
• Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial.

  2011cited by this paper
• Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.

  2011cited by this paper
• Safety of anacetrapib in patients with or at high risk for coronary heart disease.

  2010cited by this paper
• The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors.

  2009cited by this paper
• Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.

  2009cited by this paper
• Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone

  2008cited by this paper
• Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk.

  2008cited by this paper
• Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk.

  2008cited by this paper
• Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits Published, JLR Papers in Press, February 26, 2007.

  2007cited by this paper
• Effects of torcetrapib in patients at high risk for coronary events.

  2007cited by this paper
• Effect of torcetrapib on the progression of coronary atherosclerosis.

  2007cited by this paper
• Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.

  2007cited by this paper
• Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia

  2007cited by this paper
• Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial.

  2007cited by this paper
• Reconstituted High-Density Lipoproteins Inhibit the Acute Pro-Oxidant and Proinflammatory Vascular Changes Induced by a Periarterial Collar in Normocholesterolemic Rabbits

  2005cited by this paper
• Antiinflammatory Properties of HDL

  2004cited by this paper
• Raising High-Density Lipoprotein in Humans Through Inhibition of Cholesteryl Ester Transfer Protein: An Initial Multidose Study of Torcetrapib

  2004cited by this paper
• Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.

  2004cited by this paper
• Cholesteryl Ester Transfer Protein: A Novel Target for Raising HDL and Inhibiting Atherosclerosis

  2003influential reference
• A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits

  2000cited by this paper
• Vaccine-Induced Antibodies Inhibit CETP Activity In Vivo and Reduce Aortic Lesions in a Rabbit Model of Atherosclerosis

  2000cited by this paper
• CETP and atherosclerosis.

  2000cited by this paper
• Effect of Antisense Oligonucleotides against Cholesteryl Ester Transfer Protein on the Development of Atherosclerosis in Cholesterol-fed Rabbits*

  1998cited by this paper

• Cholesteryl Ester Transfer Protein Inhibitors: State of the Science

  2026cites this paper
• Chikungunya Replication and Infection Is Dependent upon and Alters Cellular Hexosylceramide Levels in Vero Cells

  2025cites this paper
• Decoding Structural Fingerprints to Design and Elucidate the Mechanism of Action of Prospective Cholesteryl Ester Transfer Protein Drugs

  2025cites this paper
• Cholesteryl Ester Transfer Protein Inhibitors for Dyslipidemia in Cardiovascular Risk Patients: A Systematic Review and Meta-Analysis

  2025cites this paper
• Role of CETP, PCSK-9, and CYP7-alpha in cholesterol metabolism: Potential targets for natural products in managing hypercholesterolemia.

  2024cites this paper
• Managing Dyslipidemia in Children: Current Approaches and the Potential of Artificial Intelligence.

  2024cites this paper
• Chemical Synthesis, Biological Evaluation, and Cheminformatics Analysis of a Group of Chlorinated Diaryl Sulfonamides: Promising Inhibitors of Cholesteryl Ester Transfer Protein.

  2024cites this paper
• Novel and future lipid-modulating therapies for the prevention of cardiovascular disease

  2023cites this paper
• Genetics-based risk scores for prediction of premature coronary artery disease

  2023cites this paper
• New Cholesteryl Ester Transfer Protein from Indonesian Herbal Plants as Candidate Treatment of Cardiovascular Disease

  2022cites this paper
• Hyperlipidemia management in diabetes: First line or supportive therapy?

  2022cites this paper
• Structure of New Ferroverdins Recruiting Unconventional Ferrous Iron Chelating Agents

  2022cites this paper
• Pharmacogenetics-guided CETP inhibition: an open question?

  2022cites this paper
• Newer and Emerging LDL-C Lowering Agents and Implications for ASCVD Residual Risk

  2022cites this paper
• Genetics of Cholesterol-Related Genes in Metabolic Syndrome: A Review of Current Evidence

  2022cites this paper
• Long-term Benefits and Harms Associated With Genetic Cholesteryl Ester Transfer Protein Deficiency in the General Population.

  2021cites this paper
• Treatment of Dyslipidaemia in Children

  2021cites this paper
• Toward a Best-in-Class Inhibitor of Cholesteryl Ester Transfer Protein (CETP).

  2021cites this paper
• Subcutaneous Administration of Apolipoprotein J-Derived Mimetic Peptide d-[113–122]apoJ Improves LDL and HDL Function and Prevents Atherosclerosis in LDLR-KO Mice

  2020cites this paper